JANN N SARKARIA, M.D.
Radiology at 1 St, Rochester, MN
License number
Minnesota 39688
Category
Radiology
Type
Radiation Oncology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Professional information
Dr. Jann N Sarkaria, Rochester MN - MD (Doctor of Medicine)
Specialties:
Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Radiation Oncology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of California, Los Angeles, School Of Medicine
Graduated: 1990
University Hi J a Burns School Med
University Of Wi Hospital and Cli
University Of California, Los Angeles, School Of Medicine
Graduated: 1990
University Hi J a Burns School Med
University Of Wi Hospital and Cli
Jann Nagina Sarkaria, Rochester MN
Specialties:
Radiology, Radiation Oncology, Medical Oncology
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
University of California at Los Angeles (1990)
Predicting Responsiveness To Temozolomide
US Patent:
2010020, Aug 12, 2010
Filed:
Jun 11, 2008
Appl. No.:
12/664143
Inventors:
Jann N. Sarkaria - Rochester MN, US
Gasper J. Kitange - Rochester MN, US
Brett L. Carlson - Owatonna MN, US
Mark A. Schroeder - Rochester MN, US
Ann C.M. Tuma - Mantorville MN, US
Paul A. Decker - Rochester MN, US
Wenting Wu - Rochester MN, US
Gasper J. Kitange - Rochester MN, US
Brett L. Carlson - Owatonna MN, US
Mark A. Schroeder - Rochester MN, US
Ann C.M. Tuma - Mantorville MN, US
Paul A. Decker - Rochester MN, US
Wenting Wu - Rochester MN, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
This document features methods and materials involved in predicting responsiveness of a mammal (e.g., human) having cancer (e.g., glioblastoma multiforme) to treatment with chemotherapy (e.g., temozolomide). For example, methods and materials for using the methylation status at one or more CpG methylation sites (e.g., CpG 89) in O6-methylguanine methyl-transferase nucleic acid to determine whether or not a mammal having cancer is responsive to treatment with chemotherapy (e.g., temozolomide) are provided.